Global Eczema Therapeutics Market – Restraints
Increasing delays in the drug approvals from the regulatory authorities for the treatment of eczema is expected to increase the growth of the global eczema therapeutics market over the forecast period. For instance, on June 16, 2021, the U.S. Food and Drug Administration (U.S. FDA) delayed further decisions for AbbVie Inc.’s Rinvoq and Eli Lily and Company’s Olumiant, which have been indicated for the treatment of moderate to severe atopic dermatitis. The drugs belong to the JAK class of medicines, and the medicines from this drug class has been associated with severe side effects such as blood clots, cancers etc.
The termination of the clinical trials, which was directed for the development of the drug for eczema, is expected to hamper the growth of the market over the forecast period. For instance, in 2019, Galapagos NV and MorphoSys AG ended their agreement with Novartis AG for the development of the drug MOR106, which was directed for the development for the atopic dermatitis. Novartis AG reported negative results during the Phase II trial for MOR106. The above factors are expected to restrain the growth of the global eczema therapeutics market over the forecast period.
Eczema Therapeutics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients